Review: Staphylococcus aureus and MRSA in cystic fibrosis

Goss, Christopher H.; Muhlebach, Marianne S.

doi:10.1016/j.jcf.2011.06.002

Cited by 187 publications

(173 citation statements)

References 76 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of MRSA in Canada and Europe is lower, ranging from 3 to 11% of patients with CF (30). Chronic MRSA infection in patients with CF is associated with increased rate of lung function decline, failure to recover lung function after a pulmonary exacerbation, and decreased survival (8,31,32).…”

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

“…The approach to patients with CF with MRSA infection seen in the outpatient clinic has recently been reviewed (30). Doe and colleagues (41) reported that patient segregation and aggressive antibiotic eradication therapy can achieve eradication in the majority of patients with CF.…”

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

“…Numerous antibiotic regimens were used; however, the most successful were those regimens that included two oral antibiotics (one of which was rifampin) and nebulized vancomycin. Rifampin has been a component of successful MRSA eradication protocols due to its high mucosal concentrations and activity against biofilms, but it should be used in combination with another antibiotic as resistance develops quickly with monotherapy (30). Rifampin can also be associated with worsening gastroesophageal reflux and decreased efficacy of oral contraceptives (42).…”

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

See 2 more Smart Citations

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

et al. 2014

View full text Add to dashboard Cite

Despite significant advances in treatment strategies targeting the underlying defect in cystic fibrosis (CF), airway infection remains an important cause of lung disease. In this two-part series, we review recent evidence related to the complexity of CF airway infection, explore data suggesting the relevance of individual microbial species, and discuss current and future treatment options. In Part I, the evidence with respect to the spectrum of bacteria present in the CF airway, known as the lung microbiome is discussed. Subsequently, the current approach to treat methicillin-resistant Staphylococcus aureus, gram-negative bacteria, as well as multiple coinfections is reviewed. Newer molecular techniques have demonstrated that the airway microbiome consists of a large number of microbes, and the balance between microbes, rather than the mere presence of a single species, may be relevant for disease pathophysiology. A better understanding of this complex environment could help define optimal treatment regimens that target pathogens without affecting others. Although relevance of these organisms is unclear, the pathologic consequences of methicillin-resistant S. aureus infection in patients with CF have been recently determined. New strategies for eradication and treatment of both acute and chronic infections are discussed. Pseudomonas aeruginosa plays a prominent role in CF lung disease, but many other nonfermenting gram-negative bacteria are also found in the CF airway. Many new inhaled antibiotics specifically targeting P. aeruginosa have become available with the hope that they will improve the quality of life for patients. Part I concludes with a discussion of how best to treat patients with multiple coinfections.

show abstract

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

See 1 more Smart Citation

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Over 90% of S. aureus isolates encode β-lactamase, eliminating certain penicillins as useful antibiotics [63]. While penicillinase-resistant penicillins are available, they are usually limited to treatment of severe MSSA infection.…”

Section: As a Primarily Extracellular Pathogen The Microbial Surfacementioning

confidence: 99%

“…aureus is typically the first organism that colonizes the CF lung and remains the most common CF isolate in individuals under 25, with prevalence of S. aureus colonization peaking between ages 11-15 [63,70]. Rates of MRSA infection during childhood are substantially higher in the United States than in Europe [70].…”

Section: As a Primarily Extracellular Pathogen The Microbial Surfacementioning

confidence: 99%

Burkholderia cenocepacia J2315-mediated destruction of Staphylococcus aureus NRS77 biofilms.

Thompson¹

View full text Add to dashboard Cite

Unraveling the Antibacterial and Iron Chelating Activity ofN‐Oxide Hydroxy‐Phenazine natural Products and Synthetic Analogs againstStaphylococcus aureus

Alatawneh

Meijler

2023

Israel Journal of Chemistry

View full text Add to dashboard Cite

Phenazines are redox‐active secondary metabolites produced by many microorganisms, especially by bacteria. These compounds are often produced at high cell densities in various niches. Pseudomonas strains are the most common phenazine producers, and phenazine production in these bacteria is controlled by quorum sensing, a mechanism that enables bacteria to collectively respond to changes in cell density. As phenazines exhibit a wide range of activities against many different species, this has led to increased interest and studies related to their mechanisms of action. In this work, we have investigated and evaluated the activity of an array of phenazine‐based natural products and their analogs on Gram‐positive bacteria that share the same natural niches with Pseudomonas, such as the human pathogen Staphylococcus aureus. This human pathogen plays a major role in lung infections and is often found in such infections together with P. aeruginosa. Among the screened compounds, hydroxyl‐containing phenazines with a 5,10‐dioxide scaffold were found to exhibit potent inhibitory effects on the growth of S. aureus. The natural product iodinin (1,6‐dihydroxyphenazine 5,10‐dioxide, 6), which was chosen as a model for this class of compounds has been found to strongly chelate iron (II), thus we examined the potential role of iron starvation in suppressing the growth of this pathogen by these phenazines that are generally linked to reactive oxygen species formation mechanisms. Our results suggest that chelation of essential metals, leading to a lack of important nutrients could have a significant contribution to the antibacterial activity of these phenazines, alongside with ROS production, DNA damage and oxidative stress.

show abstract

Review: Staphylococcus aureus and MRSA in cystic fibrosis

Abstract: To advance the care of CF patients, controlled clinical trials are urgently needed to find the optimal approach to treating CF patients who are infected with either MSSA or MRSA.

Cited by 187 publications

References 76 publications

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

Burkholderia cenocepacia J2315-mediated destruction of Staphylococcus aureus NRS77 biofilms.

Unraveling the Antibacterial and Iron Chelating Activity ofN‐Oxide Hydroxy‐Phenazine natural Products and Synthetic Analogs againstStaphylococcus aureus

Contact Info

Product

Resources

About